US Stock Insider Trading | Nektar Therapeutics disclosed two insider trading transactions on February 20

K-LinePoet · 2026-02-21T23:05:20+00:00

On February 20, 2026, NKTR disclosed two insider trading transactions. Director ROBIN HOWARD W sold 423 shares on February 18, 2026.【Recent Insider Transactions】| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share/USD | Total Amount/USD || --- | --- | --- | --- | --- | --- | --- | --- || February 20, 2026 | Executive | Zalevsky Jonathan | February 18, 2026 | Sell | 180 | 73.00 | $13,100 || February 20, 2026 |

K-LinePoet

2026-02-21 23:05:20

On February 20, 2026, Nektar Therapeutics (NKTR) disclosed two insider trading transactions. Director ROBIN HOWARD W sold 423 shares on February 18, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 20, 2026	Executive	Zalevsky Jonathan	February 18, 2026	Sell	180	73.00	13,100
February 20, 2026	Director	ROBIN HOWARD W	February 18, 2026	Sell	423	73.00	30,900
January 22, 2026	Executive	Zalevsky Jonathan	January 20, 2026	Sell	3,867	35.67	137,900
November 25, 2025	Executive	Wilson Mark Andrew	November 25, 2025	Sell	630	54.28	34,200
November 25, 2025	Director	ROBIN HOWARD W	November 25, 2025	Sell	2,207	54.28	119,800
November 25, 2025	Executive	Zalevsky Jonathan	November 25, 2025	Sell	1,157	54.28	62,800
September 11, 2025	Director	ROBIN HOWARD W	September 9, 2025	Sell	1,210	48.18	58,300
September 11, 2025	Director	ROBIN HOWARD W	September 9, 2025	Sell	1,200	46.41	55,700
September 11, 2025	Director	ROBIN HOWARD W	September 9, 2025	Sell	2,100	45.16	94,800
September 11, 2025	Director	ROBIN HOWARD W	September 9, 2025	Sell	2,156	47.49	102,400

[Company Profile]

Nektar Therapeutics was founded in California in 1990 and re-registered in Delaware in 1998. The company is a clinical-stage, research-focused biopharmaceutical company specializing in drug discovery. It focuses on discovering and developing innovative drugs in the field of immunotherapy. In this rapidly growing area, the company is dedicated to creating new immunomodulators that selectively induce, amplify, weaken, or block immune responses to achieve desired therapeutic effects.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.